Wednesday, June 10, 2026
🇺🇸 FDA

pharma

Amarin Neuroscience

Amarin Neuroscience Ltd

NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.

GB HQ
EMA registrant Type
Company details
Status
Public
HQ
GB
Programs
0
Drugs
0
Patents
11
Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Amarin Neuroscience — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.

All News Analysis

1 articles

Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
High impact NewsJun 5, 2026

Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case

US Supreme Court · 5 min

The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.